LncRNA NKILA Suppresses TGF‐β‐induced Epithelial–mesenchymal Transition by Blocking NF‐κB Signaling in Breast Cancer
Wei Wu,Fei Chen,Xiuying Cui,Limei Yang,Jianing Chen,Jinghua Zhao,Di Huang,Jiang Liu,Linbin Yang,Jiayi Zeng,Zhiqing Zeng,Yunbao Pan,Fengxi Su,Junchao Cai,Zhongfu Ying,Qiyi Zhao,Erwei Song,Shicheng Su
DOI: https://doi.org/10.1002/ijc.31605
2018-01-01
International Journal of Cancer
Abstract:TGF-β plays a central role in mediating epithelial-mesenchymal transition (EMT) by activating the Smad pathway. In addition, accumulating evidence suggests that TGF-β-induced EMT is NF-κB-dependent in various cancer types. However, it is largely unclear if NF-κB mediates TGF-β-induced EMT in breast cancer, and if this mediation occurs, the regulatory mechanisms are unknown. In our study, we found that TGF-β activates the NF-κB pathway. Inhibition of NF-κB signaling markedly abrogates TGF-β-induced EMT. By studying the regulatory mechanism of TGF-β-induced NF-κB signaling, we found that lncRNA NKILA was upregulated by TGF-β and was essential for the negative feedback regulation of the NF-κB pathway. Accordingly, overexpression of NKILA significantly reduced TGF-β-induced tumor metastasis in vivo. Consistent with the results from mice, the expression of NKILA was negatively correlated with EMT phenotypes in clinical breast cancer samples. Collectively, our study indicated that the NKILA-mediated negative feedback affects TGF-β-induced NF-κB activation and that NKILA may be a therapeutic molecule in breast cancer metastasis via inhibition of EMT.